Why Bristol Myers Squibb (BMY) Stock Is Up Today

Bristol Myers Squibb (BMY) is up 3.0% today. Here is some analysis on what might have caused this price movement.

Analysis: The most likely driver is continued investor optimism after the company’s August 13, 2026 FDA approval for Zenbexus in multiple myeloma, which added a new commercial growth catalyst. Strength from Bristol Myers Squibb’s late-July earnings report and higher full-year guidance also appears to be reinforcing the move.

Details:

The FDA granted accelerated approval on August 13 for Zenbexus, Bristol Myers Squibb’s first CELMoD therapy, for certain adults with multiple myeloma.

In its second-quarter 2026 results, the company said revenue rose 6% to $13.0 billion, with Growth Portfolio revenue up 15%, pointing to improving product momentum.

Bristol Myers Squibb raised its 2026 revenue outlook to about $49.0 billion to $50.0 billion and lifted its non-GAAP EPS range to $6.75 to $7.00.

Recent positive sentiment may also be getting support from improved Wall Street expectations after an early-August analyst upgrade, though the approval and guidance increase look like the bigger catalysts.

Sources:

U.S. FDA, Bristol Myers Squibb, SEC

Disclaimer: This price movement analysis was generated with the help of AI. Please double-check the information provided for mistakes.

$BMY Insider Trading Activity

$BMY insiders have traded $BMY stock on the open market 2 times in the past 6 months. Of those trades, 0 have been purchases and 2 have been sales.

Here’s a breakdown of recent trading of $BMY stock by insiders over the last 6 months:

DAVID V ELKINS (EVP, Chief Financial Officer) has made 0 purchases and 2 sales selling 30,000 shares for an estimated $1,850,016.

To track insider transactions, check out Quiver Quantitative's insider trading dashboard. You can access data on insider stock transactions through the Quiver Quantitative API insider transaction endpoint.

EARLY ACCESS

Receive BMY Data Alerts

Real-time alerts on filings, insider trades, and market signals — before everyone else.

Get Alerts →

$BMY Hedge Fund Activity

We have seen 1,173 institutional investors add shares of $BMY stock to their portfolio, and 1,274 decrease their positions in their most recent quarter.

Here are some of the largest recent moves:

JPMORGAN CHASE & CO added 71,713,442 shares (+inf%) to their portfolio in Q2 2026, for an estimated $4,132,128,528
SIXTH STREET PARTNERS MANAGEMENT COMPANY, L.P. added 67,595,177 shares (+inf%) to their portfolio in Q2 2026, for an estimated $3,894,834,098
PRICE T ROWE ASSOCIATES INC /MD/ added 21,457,405 shares (+209.3%) to their portfolio in Q2 2026, for an estimated $1,236,375,676
BLACKROCK, INC. added 8,702,106 shares (+5.1%) to their portfolio in Q2 2026, for an estimated $501,415,347
PACER ADVISORS, INC. added 7,995,711 shares (+inf%) to their portfolio in Q2 2026, for an estimated $460,712,867
CHARLES SCHWAB INVESTMENT MANAGEMENT INC added 6,479,804 shares (+10.6%) to their portfolio in Q2 2026, for an estimated $373,366,306
NORDEA INVESTMENT MANAGEMENT AB added 6,019,226 shares (+296.1%) to their portfolio in Q2 2026, for an estimated $346,827,802

To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API 13F endpoint.

$BMY Government Contracts

We have seen $11,451,557 of award payments to $BMY over the last year.

Here are some of the awards which we have have seen pay out the most over the last year:

REVLIMID, POMALYST, CAMZYOS SPECIALTY PHARMACEUTICALS: $848,445
ABECMA FOR CAR-T: $378,650

To track government contracts to publicy traded companies, check out Quiver Quantitative's government contracts dashboard. You can access data on government contracts through the Quiver Quantitative API government contracts endpoint.

$BMY Congressional Stock Trading

Members of Congress have traded $BMY stock 2 times in the past 6 months. Of those trades, 1 have been purchases and 1 have been sales.

Here’s a breakdown of recent trading of $BMY stock by members of Congress over the last 6 months:

REPRESENTATIVE MIKE KELLY sold up to $50,000 on 05/07.
SENATOR ALAN ARMSTRONG purchased up to $15,000 on 03/27.

To track congressional stock trading, check out Quiver Quantitative's congressional trading dashboard. You can access data on congressional stock trades through the Quiver Quantitative API Congress trades endpoint.

$BMY Analyst Ratings

Wall Street analysts have issued reports on $BMY in the last several months. We have seen 1 firms issue buy ratings on the stock, and 0 firms issue sell ratings.

Here are some recent analyst ratings:

Piper Sandler issued a "Overweight" rating on 02/23/2026

To track analyst ratings and price targets for $BMY, check out Quiver Quantitative's $BMY forecast page.

$BMY Price Targets

Multiple analysts have issued price targets for $BMY recently. We have seen 6 analysts offer price targets for $BMY in the last 6 months, with a median target of $63.5.

Here are some recent targets:

Carter Gould from Cantor Fitzgerald set a target price of $54.0 on 07/06/2026
Tim Anderson from B of A Securities set a target price of $67.0 on 04/09/2026
Seamus Fernandez from Guggenheim set a target price of $72.0 on 04/08/2026
Rajesh Kumar from HSBC set a target price of $60.0 on 03/17/2026
Trung Huynh from RBC Capital set a target price of $60.0 on 02/25/2026
David Amsellem from Piper Sandler set a target price of $75.0 on 02/23/2026

This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.